521 0 Kommentare Novavax to Present RSV Vaccine Clinical Data at the 8th Vaccine & ISV Congress in Philadelphia on Sunday, October 26

GAITHERSBURG, Md., Oct. 23, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Gregory Glenn, M.D., Senior Vice President, Research and Development at Novavax will present new immunogenicity data from Novavax' RSV F-Protein Nanoparticle vaccine candidate (RSV F vaccine) clinical trials at the 8th Vaccine & ISV Congress to be held October 26-28, 2014 in Philadelphia, PA at the Hilton Philadelphia City Avenue Hotel.

The session presentation title, date and time is listed below:

Vaccines against Viral Pathogens

Sunday, October 26, 2014, 3:10 to 3:15 p.m. Immunogenicity of the RSV nanoparticle vaccine in humans and the induction of palivizumab competing antibodies: Review of immunogenicity data from 4 recent clinical trials

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases.

CONTACT: Barclay A. Phillips
         SVP, Chief Financial Officer and Treasurer
         Novavax, Inc.
         240-268-2000
         
         David Schull or Andrea Flynn, Ph.D.
         Russo Partners, LLC
         (212)-845-4271
         (646) 942-5631
         David.schull@russopartnersllc.com
         Andrea.flynn@russopartnersllc.com

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire